Natera, Inc. (NTRA) Stock

Healthcare · Diagnostics & Research · Member of Other US Stocks

Natera, Inc. (NTRA) closed at USD 404.79 on 2026-10-15, a change of +109.9 % over the past year, with a market capitalization of USD 56.71B.

Natera, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Natera, Inc. key figures

Previous close

USD 404.79 (2026-10-15)

1-year change

+109.9 %

Market cap

USD 56.71B

Enterprise value

USD 55.86B

P/E ratio (trailing)

-291.44

P/E ratio (forward)

-1,707.94

EPS (trailing)

-1.35

EPS (forward)

-0.23

PEG ratio

n/a

Price to book

31.02

Revenue growth

37.7 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.14

Employees

6,135

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Natera, Inc.

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Natera, Inc. and compare it with other stocks.